

UC Irvine

UC Irvine Previously Published Works

Title

No Reduction in Surgical Site Infection Obtained with Post-Operative Antibiotics in Facial Fractures, Regardless of Duration or Anatomic Location: A Systematic Review and Meta-Analysis

Permalink

<https://escholarship.org/uc/item/2wp4924x>

Journal

Surgical Infections, 21(2)

ISSN

1096-2964

Authors

Delaplain, Patrick T
Phillips, Jacquelyn L
Lundeberg, Megan
[et al.](#)

Publication Date

2020-03-01

DOI

10.1089/sur.2019.149

Peer reviewed

No Reduction in Surgical Site Infection Obtained with Post-Operative Antibiotics in Facial Fractures, Regardless of Duration or Anatomic Location: A Systematic Review and Meta-Analysis

Patrick T. Delaplain,¹ Jacquelyn L. Phillips,² Megan Lundeborg,³ Jeffry Nahmias,¹ Catherine M. Kuza,⁴ Brian M. Sheehan,¹ Linda S. Murphy,⁵ Marija Pejcinovska,⁶ Areg Grigorian,¹ Viktor Gabriel,¹ Philip S. Barie,⁷ and Sebastian D. Schubert¹

Abstract

Background: We performed a systematic review of the literature on antibiotic prophylaxis practices in open reduction, and internal fixation of, facial fracture(s) (ORIFfx). We hypothesized that prolonged antibiotic prophylaxis (PAP) would not decrease the rate of surgical site infections (SSIs).

Methods: We performed a systematic review of four databases: PubMed, CENTRAL, EMBase, and Web of Science, from inception through January 15, 2017. Three independent reviewers extracted fracture location (orbital, mid-face, mandible), antibiotic use, SSI incidence, and time from injury to surgery. Mantel-Haenszel and generalized estimating equations were carried out independently for each fracture zone.

Results: Of the 587 articles identified, 54 underwent full-text review, yielding 27 studies that met our inclusion criteria. Of these, 16 studies (n=2,316 patients) provided data for mandible fractures, four studies (n=439) for mid-face fractures, and six studies (n=377) for orbital fractures. Pooled analysis of each fracture type's SSI rate showed no statistically significant association with the odds ratio (OR) of developing an SSI. For mandible fractures treated with ORIFfx, the OR for an SSI after 24–72 hours of prophylaxis relative to <24 hours was 0.85 (95% confidence interval [CI] 0.62–1.17), whereas for >72 hours compared with <24 hours, the OR was 1.42 (95% CI 0.96–2.11). For mid-face fractures, there was no improvement in SSI rate from PAP (OR 1.05; 95% CI 0.20–5.63).

Conclusions: We did not demonstrate a lower rate of SSI associated with PAP for any ORIFfx repair. Post-operative antibiotics for >72 hours paradoxically may increase the SSI risk after mandible fracture repairs.

Keywords: antibiotics; facial fractures; surgical site infections

FACIAL FRACTURES account for more than 260,000 emergency department visits each year in the United States [1,2]. Nearly 40% of these injuries require open surgical management [3]. Avoidance of surgical site infections (SSIs), especially in the setting of implanted hardware, is crucial; and there is a broad consensus that the administration of

prophylactic antibiotics post-operatively helps reduce this risk [4–6]. However, the role of antibiotic prophylaxis (PAP) for more than 24 hours in the operative management of facial fractures is controversial. Two studies, published more than 30 years ago, encouraged widespread use of PAP in facial fractures [4,5]. However, contemporary data suggest that

¹Department of Surgery, University of California, Irvine Medical Center, Orange, California.

²Department of Surgery, University of California, San Francisco East Bay, San Francisco, California.

³Legacy Emanuel Medical Center, Portland, Oregon.

⁴Department of Anesthesiology, University of Southern California, Los Angeles, California.

⁵Reference Department, University of California-Irvine Libraries, NS, ⁶Center for Statistical Consulting, University of California, Irvine, Irvine, California.

⁷Department of Surgery, Weill Cornell Medical College at New York/Presbyterian Hospital, New York, New York.

*Presented at the 37th Annual Meeting of the Surgical Infection Society, Westlake Village, California, April 22–25, 2018.

PAP with open reduction and internal fixation of facial fractures (ORIFfx) likely is unnecessary [6–14]. Despite these findings, a review from 2015 included a survey of US plastic surgeons that found that 75% employ PAP routinely for >24 hours, and the majority of respondents reported continuing antibiotic prophylaxis for at least one week [15]. This practice is potentially problematic, as the emergence of multi-drug-resistant organisms and antibiotic-linked complications (e.g., *Clostridioides difficile* colitis) create substantive healthcare issues. Furthermore, these complications are associated with greater morbidity, length of stay, deaths, and healthcare costs [16–19].

Habib et al. performed a systematic review and meta-analysis of 13 studies on post-operative antibiotic prophylaxis for facial fractures [20] and demonstrated that there was no discernible difference in the SSI rate between those individuals who received PAP (>24 hours) and individuals who received <24 hours of antibiotic prophylaxis. Although the study was well designed, it did not differentiate between the duration of antibiotic prophylaxis behind a binary point around 24 hours, and their analysis by anatomic fracture location was limited.

Our understanding of infection and the limitations of antibiotic prophylaxis continues to improve, and shorter courses of antibiotics are being implemented in many diseases [21–23]. The mounting evidence against PAP for facial fractures prompted this systematic review and meta-analysis focusing on different durations of prophylaxis. To avoid further dilution of already heterogeneous data and isolate fracture patterns with likely disparate infection rates, we elected to review the three major zones (i.e., orbital, mid-face, mandible) of facial fractures discretely (i.e., analysis of mandibular fractures apart from orbital and mid-face fractures). We hypothesized that the use of PAP after ORIFfx would not decrease the rate of post-operative SSIs for any anatomic fracture zone.

Methods

Search strategy

A systematic search of PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), EMBase, and Web of Science was performed to retrieve studies published from the inception of the databases to January 15, 2017. The Preferred Reported Items for Systematic-Reviews and Meta-Analyses (PRISMA) guidelines were followed where possible [24]. We included randomized controlled trials (RCTs) and prospective, observational, retrospective, cohort, and case-control studies focused on prophylactic antibiotic use in pre- and post-operative patients with acute facial fractures. We developed the optimal search strategy in PubMed and applied filters to restrict the final search results to adult participants (Supplement 1). The search strategy was modified as necessary for use in the Cochrane Library (Wiley InterScience, John Wiley and Sons, Inc., Hoboken NJ), EMBase (Elsevier, Inc., Atlanta, GA), and Web of Science (Clarivate Analytics, Philadelphia, PA) databases.

Clinicaltrials.gov also was searched to identify any ongoing or recently completed trials. Additionally, we contacted principal investigators of clinical trials that we identified in Clinicaltrials.gov for potential unpublished studies, but no additional studies were obtained. All search results were

managed in EndNote v. 8 (Clarivate Analytics), wherein duplicate studies were removed.

Inclusion/exclusion criteria

The search was restricted to peer-reviewed manuscripts of original research published within the time-frame of our search. For inclusion in this meta-analysis, the study participants must have undergone an operative intervention for facial fracture, with a reported post-operative SSI rate, of the mandible, orbit, and mid-face (including fractures of the zygomatic arch of the temporal bone and maxillary fractures except for the infraorbital rim, whether or not of the LeFort type). Parietal, temporal (except for the zygomatic arch), or frontal bone skull fractures were excluded. Each study also had to provide a duration of antibiotic administration and clear identification of which study participants received a particular post-operative antibiotic course. We placed no restrictions on the type or timing of operative intervention performed or the type or class of antibiotic administered. Facial fractures of non-traumatic origin or from an existing condition were not included. Studies that did not identify clearly the anatomic fracture location were included in a subgroup of “mixed” fracture patients. Studies performed in pediatric patients (≤ 18 years old) were excluded. Systematic reviews were not considered for inclusion, nor were opinion articles or case reports.

Classification of studies

Each study was classified according to the National Health and Medical Research Council levels of evidence [25]. A study was included if it compared an intervention with a control group, irrespective of randomization (Level II and III studies). In order to maximize the number of studies selected for analysis, studies were included if they followed a clinical effectiveness design wherein outcomes were compared before and after the institution of an intervention (Level III and IV studies).

Study selection

Titles and abstracts were screened independently by three reviewers for eligibility, with each reviewer assessing two-thirds of the identified candidate studies. Any discrepancies among reviewers were mediated by a senior reviewer (JN). Included studies then underwent full-text review to confirm that sufficient data were present and that the inclusion criteria were met. A flow chart of the study selection process can be seen in Fig. 1.

Data extraction

Extracted data were: (1) Publication year; (2) study design; (3) number of years studied; (4) age range of study subjects; (5) number of study subjects; (6) follow-up interval; (7) types of fractures; (8) antibiotic duration; (9) antibiotic used; and (10) time from injury to intervention. For each study, the relevant antibiotics administered were classified into three general categories, with all patients receiving pre-operative antibiotics: Peri-operative (<24 hours post-operatively), post-operative (24–72 hours post-operatively), and extended post-operative (>72 hours after surgery).




FIG. 1. Overview of literature search and review for manuscripts included in meta-analysis.

Risk of bias/study quality assessment

Because we included RCTs as well as non-randomized prospective and retrospective studies, we employed the modified Downs and Black checklist [26] to determine the risk of bias. This form was completed for each of the included studies by an independent reviewer not involved in the initial data collection (Supplement 2). It focuses on several domains of study quality, including reporting of data, external validity, internal validity (bias and confounding/selection bias), and power. Study quality was then reported (Table 1) on the basis of the score as a categorical rank: Excellent (26–28 points), good (20–25), fair (15–19), and poor (≤ 14).

Meta-analysis and data synthesis

To present meaningfully the association between the development of post-operative SSI and the prophylactic use of antibiotics, the focus of the data synthesis was an estimate of the odds ratio (OR). Given the great deal of disparity in how findings were presented in different studies, two approaches were taken in the quantitative synthesis of the data. Studies that provided clear information on SSI rates for two or more of the general antibiotic treatment groups were tabulated and analyzed using the Mantel-Haenszel (MH) approach [27]. A number of studies assessed the rate of SSI for only a single prophylactic regimen; in an effort to utilize as much as possible of the available literature, we employed generalized estimating equations (GEEs) to arrive at marginal (population-wide) estimates of the odds of developing an SSI given a particular prophylactic regimen. Exchangeable cor-

relation structure was assumed for the models, and a robust variance estimator was used.

Results

We identified 787 abstracts via the database search, and, after exclusion of duplicates, there were 587 articles that underwent screening. On full-text review, 35 articles met the criteria for qualitative synthesis, although eight could not be included in the final quantitative analysis because of insufficient data (Fig. 1). In the end, 11 articles had sufficient data to be included in the MH meta-analysis (Nos. 4, 12, 13, 28–35); 20 articles (including most of the MH group) were used in the GEE approach (Nos. 4, 8, 11, 12, 28–31, 33–44), and five studies were used only for pooled data regarding the incidence of SSI (Nos. 14, 45–48) (Table 1).

During the final analysis, 16 studies contributed to the data on SSI and antibiotic use in patients with mandibular fractures (Nos. 4, 11, 12, 28–31, 33–35, 37, 38, 40, 42–44), four to mid-face fractures (Nos. 13, 32, 44, 46), six to orbital fractures (Nos. 14, 44–48), and four to mixed fractures (Nos. 8, 36, 39, 41). Pooled analysis was carried out separately for each fracture type whenever enough information was available. Results per fracture type are presented in more detail in the sections below.

Mandibular fractures: ORIF with or without maxillomandibular fixation (MMF)

Sixteen studies (Nos. 4, 11, 12, 28–31, 33–35, 37, 38, 40, 42–44) were included in our analysis of post-operative

TABLE 1. SUMMARY OF STUDIES USED IN QUANTITATIVE META-ANALYSIS

<i>Authors (Year)</i>	<i>Trial type</i>	<i>Follow-up</i>	<i>N</i>	<i>Fracture type</i>	<i>Intravenous drug(s)</i>	<i>Oral drug(s)</i>	<i>Comparison groups</i>	<i>Study quality</i>
Studies used in Mantel-Hanszel analyses (n = 11)								
Abubaker et al. (2001) ^a	RCT	6 wks	30	Mandible	Penicillin G	Penicillin VK	A: Peri-op B: Extended	Good
Bouchard et al. (2014) ^a	Retrospective cohort	1 wk	108	Mandible	N/S	N/S	A: Peri-op B: Post-op	Fair
Domingo et al. (2016) ^a	Retrospective cohort	4 wks	359	Mandible	Variable	Variable	C: Extended A: Peri-op B: Post-op	Good
Gaal et al. (2016) ^a	Retrospective cohort	N/S	510	Mandible	N/S	N/S	C: Extended A: Peri-op	Good
Knepil et al. (2010)	Prospective cohort	30 d	134	Mid-face	A: cefuroxime ± metronidazole B: amoxicillin/clavulanic acid C: co-fluampicillin ± metronidazole	NA	B: Extended A: Peri-op B: Post-op	Fair
Miles et al. (2006) ^a	RCT	5–8 wks	181	Mandible	Cefazolin + penicillin G IM	Clindamycin	C: Extended A: Peri-op B: Post-op	Good
Schaller et al. (2013) ^a	RCT	6 mos	59	Mandible	Amoxicillin/clavulanic acid	Augmentin	A: Post-op B: Extended	Good
Singh et al. (2013) ^a	Prospective cohort	1–4 wks	302	Mandible	Amoxicillin and metronidazole	Variable	A: Post-op B: Extended	Poor
Soong et al. (2014) ^a	RCT	6 mos	94	Mid-face	Amoxicillin/clavulanic acid	Augmentin	B: Extended A: Peri-op B: Extended	Excellent
Theriot et al. (1987) ^a	RCT	6 mos	75	Mandible	Penicillin G	Cephalexin	A: Peri-op B: Extended	Fair
Zallen et al. (1975) ^a	RCT	N/S	62	Mandible	N/S	N/S	A: Peri-op B: Extended	Poor
Studies used in general estimating equations only (n = 11)								
Adalarasan et al. (2010)	Retrospective cohort	N/S	67	Mixed	A: Penicillin VK B: Cefotaxime	N/S	A: Peri-op	Fair
Boffano et al. (2010)	Retrospective cohort	6 mos	8	Mandible	N/S	N/S	A: Extended	Fair
Bui et al. (2009)	Retrospective cohort	4–24 wks	49	Mandible	N/S	N/S	A: Extended	Fair
Campos et al. (2015)	RCT	6 wks	74	Mixed	Cefazolin	NA	A: Peri-op	Fair
Heit et al. (1997)	RCT	8 wks	90	Mandible	A: Ceftriaxone B: Penicillin G	Penicillin VK	A: Extended	Good

(continued)

TABLE 1. (CONTINUED)

<i>Authors (Year)</i>	<i>Trial type</i>	<i>Follow-up</i>	<i>N</i>	<i>Fracture type</i>	<i>Intravenous drug(s)</i>	<i>Oral drug(s)</i>	<i>Comparison groups</i>	<i>Study quality</i>
Lauder et al. (2010)	Retrospective cohort	1 wk	223	Mixed	N/S	N/S	A: Peri-op A: Extended	Good
Lindqvist et al. (1986)	Retrospective cohort	Variable	45	Mandible	N/S	N/S		Fair
Lovato et al. (2009)	Retrospective cohort	6 wks	150	Mandible	N/S	N/S	A: Peri-op B: Extended	Good
Maloney et al. (2001)	Prospective cohort	N/S	52	Mandible	A: Penicillin G B: Clindamycin	N/S	A: Peri-op B: Extended	Fair
Mottini et al. (2013)	Retrospective cohort	6 mos	339	Mixed	A: Amoxicillin/clavulanic acid B: Clindamycin	Augmentin	A: Peri-op B: Extended	Fair
Pham-Dang et al. (2013)	Retrospective cohort	N/S	393	Midface/Orbital	A: Amoxicillin/clavulanic acid B: Clindamycin	A: Augmentin B: Clindamycin	A: Extended	Fair
Studies with insufficient incidence of SSI for MHE or GEE (n = 5)								
Huang et al. (2015)	Retrospective cohort	6 wks	160	Orbital	Ampicillin and metronidazole	N/S	A: Extended	Fair
Gray et al. (1985)	Retrospective cohort	N/S	28	Midface/Orbital	N/S	N/S	A: Extended	Fair
Villarreal et al. (2002)	Prospective cohort	17 mos	32	Orbital	A: Amoxicillin/clavulanic acid	A. Augmentin	A: Peri-op B: Post-op	Fair
Wladis (2013)	Retrospective cohort	90 d → 1 y	153	Orbital	B: Clindamycin A: Cefazolin B: Clindamycin	B. Clindamycin NA	C: Extended A: Peri-op	Fair
Zix et al. (2012)	RCT	6 mos	60	Orbital	Amoxicillin/clavulanic acid	Augmentin	A: Peri-op B: Extended	Excellent

^aStudies used in both MH and GEE analysis.

Study quality based on modified Downs and Black checklist score [26]: excellent (26–28); good (20–25); fair (15–19); and poor (≤14) points.

Extended = antibiotics discontinued >72 h from surgery; IM = intramuscularly; NA = not applicable; N/S = not specified; Peri-op = antibiotics discontinued <24 h from surgery; Post-op = antibiotics discontinued 24–72 h post-operatively; RCT = randomized controlled trial.




FIG. 2. Forest plot of Mantel-Hanszel estimates of odds ratios of post-operative surgical site infections among patients in post-operative antibiotic group (antibiotics discontinued 24–72 h post-operatively) relative to the peri-operative group (antibiotics discontinued <24 h from surgery).

infection after ORIF was performed for mandibular fractures. Three studies compared SSI rates for patients treated with peri-operative antibiotics only versus post-operative antibiotics (Nos. 29, 30, 33). Eight studies compared SSI rates between peri-operative antibiotics only and extended antibiotic prophylaxis (Nos. 4, 11, 28–31, 35, 43). Four studies compared patients who received post-operative antibiotics with those who received extended antibiotic prophylaxis (Nos. 12, 29, 30, 34). Five studies had information only on a single regimen (Nos. 37, 38, 40, 42, 44).

Overall, the results of the MH analysis showed no significant association between the odds of a post-operative SSI and any of the antibiotic regimens examined. Specifically, we found no significant association between the odds of developing an SSI and the treatment regimen administered when comparisons were made between peri-operative and post-operative (OR 0.84; 95% confidence interval [CI] 0.43–1.61) (Fig. 2), or post-operative and extended prophylaxis (OR 1.17; 95% CI 0.70–1.96) (Fig. 3).

However, there was some heterogeneity among estimates in the peri-operative only and extended antibiotic groups. Specifically, the study performed by Zallen et al. appears to have an impact on the pooled estimates [4]. To capture the effect size of that particular study, MH estimates were summarized with (OR 1.42; 95% CI 0.96–2.11) (Fig. 4) and without (OR 1.63; 95% CI 1.0–82.46) (Fig. 5) this study. Exclusion of this study showed a statistically significant increase in the risk of SSI in patients who received extended antibiotic prophylaxis compared with those who received peri-operative antibiotics alone. The difference in SSI rates between the pooled studies is demonstrated further in a

L'Abbe plot (Fig. 6), in which the SSI rates of the two treatment regimens are plotted against one another for each study.

All 16 studies (4, 11, 12, 28–31, 33–35, 37, 38, 40, 42–44) were then used for further analysis using GEE estimates (Fig. 7). Similar to the MH analysis, there was no statistically significant association between the risk of developing SSI and the prophylactic antibiotic regimen.

Mid-face fractures

Two studies had sufficient data to include in an MH analysis comparing peri-operative antibiotics alone with extended antibiotic prophylaxis among those with mid-face fractures (Fig. 8) [13,32]. We found no difference in the odds of developing a post-operative SSI in the two groups (OR 1.05; 95% CI 0.20–5.63).

Among the 439 patients in this pooled group, only seven (1.6%) developed a post-operative SSI. This low incidence precludes further analysis with the GEE model.

Orbital Fractures

Six studies contributed to the incidence of post-operative SSIs in patients with orbital fractures [14,44–48]. Similar to the patients with mid-face fractures, the incidence of SSI was low (1.77%). Among 452 patients, only eight had a post-operative SSI—none of whom was in the peri-operative group. Unfortunately, insufficient comparisons were available across studies on orbital bone fractures to allow MH or GEE analysis.




FIG. 3. Forest plot of Mantel-Hanszel estimates of odds ratios of post-operative surgical site infections among patients in extended antibiotic group (antibiotics continued >72 h post-operatively) relative to post-operative antibiotic group (antibiotics discontinued 24–72 h post-operatively).




FIG. 4. Forest plot of Mantel-Hanszel estimates of odds ratio of post-operative surgical site infections among patients in extended antibiotic group (antibiotics continued >72 h post-operatively) relative to peri-operative antibiotic group (antibiotics discontinued <24 h from surgery).

Mixed fractures

We identified four studies in which the categorization of facial fractures was not well documented and thus could not be included in any of the three anatomic fracture zones [8,36,39,41]. These studies represent a heterogeneous group of 703 patients with an overall post-operative SSI incidence of 6.26%. In order to avoid bias by inclusion in a single group, these studies were analyzed separately as a “mixed” group. Unfortunately, neither GEE estimates nor MH analysis could be performed reliably, as the available data for the “mixed” treatment group were scant.

Discussion

After a thorough systematic review of the current literature, our quantitative meta-analysis demonstrated no difference in the risk of SSI for most anatomic facial fracture locations, regardless of the antibiotic prophylaxis regimen that was administered. This suggests that PAP courses likely are unnecessary. Unfortunately, the reporting of adverse antibiotic events among the examined studies was nearly absent, so it cannot be concluded directly whether PAP is harmful.

Habib et al. published recently a similar meta-analysis on the risk of SSI associated with the use of post-operative antibiotic regimens [20], which included approximately 1,200 patients across 13 studies. Whereas that study and ours came to the same principal conclusion—that PAP for facial frac-

tures is unnecessary—the focus of the two analyses is different. Habib et al. defined post-operative antibiotics as anything >24 hours, whereas our meta-analysis examined multiple regimens of post-operative antibiotics and demonstrated that both post-operative (24–72 hours) and extended (>72 hours) courses of post-operative antibiotics failed to reduce the rate of SSI.

Other major differences between the two analyses dealt with inclusion criteria and methods of quantitative analysis. Broader inclusion criteria and the use of two quantitative analyses (MH and GEE) allowed us to comment specifically on both the mandibular and mid-face fracture zones, for both of which no overall benefit was shown. In addition, we showed a greater risk of SSI with PAP in mandibular fractures. It is possible that the broader inclusion criteria employed for quantitative analysis introduced some additional bias, but if this finding is corroborated, it will be the first evidence that PAP actually may be harmful to some patients.

As expected, the findings of this study are consistent with five RCTs addressing the utility of post-operative antibiotic prophylaxis for ORIFfx (12–14,28,33). Despite accumulating evidence, a large questionnaire study found that the majority of facial surgeons in the United States use PAP for their patients, with 64%–70% choosing courses longer than 24 hours (15,49,50). This practice is not without risk, as it may expose patients needlessly to adverse reactions to antimicrobial agents, opportunistic infections such as




FIG. 5. Forest plot of Mantel-Hanszel estimates of odds ratio of post-operative surgical site infections among patients in extended antibiotic group (antibiotics continued >72 h post-operatively) relative to peri-operative antibiotic group (antibiotics discontinued <24 h from surgery) with article by Zallen et al. removed from analysis.




FIG. 6. L'Abbe plot for extended antibiotic group (antibiotics continued >72 h post-operatively) versus peri-operative antibiotic group (antibiotics discontinued <24 h from surgery). The points show surgical site infection (SSI) rates in the two groups. Solid diagonal line represents points at which studies do not differ in rate of SSI in the two groups. Points falling below this line represent studies where rate was lower in extended treatment group. Similarly, points above this line represent studies where rate was higher in extended group. Size of points is proportional to study size.

C. difficile colitis, and the emergence of resistant bacterial strains (51–53). We are unable to comment directly on adverse antibiotic-related events; this is attributable primarily to scant reporting in the surveyed studies, and the true risk to patients is unclear. We recommend that all future studies on this topic include adverse event reporting in their analyses. Additionally, PAP in the most common group of facial fracture patients—mandibular fractures undergoing ORIF—paradoxically may result in more post-operative SSIs when patients receive prolonged (>72 hours) antibiotic courses. It is possible that PAP selects resistant or more virulent organisms or that mandibular fractures in particular carry a higher bacterial burden if they are associated with an intra-oral laceration.

The duration of prophylaxis reported in the literature is heterogeneous. This led us to separate the treatment regimens into three groups that seemed to be employed most commonly: peri-operative only (<24 hours), post-operative (24–72 hours), and extended post-operative (>72 hours). This last group included a large range of antibiotic durations (five days to three weeks), which could affect the generalizability of the observations for this particular group. Regardless, we found no difference in SSIs after ORIFx regardless of the strategy employed, with the possible exception of mandibular fractures.

Another limitation of the available data is the lack of consistent reporting on the type or class of antibiotic employed. Malanchuk et al. reported that for mandibular fractures, patients given a lincosamide antibiotic had a lower rate of SSI than those treated with beta-lactam drugs, cephalosporins specifically, or aminoglycosides [54]. Those investigators hypothesized that this difference was related to oral flora, in particular anaerobic species, which are not always susceptible to agents used typically for skin/soft tissue prophylaxis, where activity against aerobic gram-positive cocci is paramount. Additionally, there is a known attrition rate in follow-up studies with the often young male patients who engage in behavior that predisposes them to facial trauma [55]. Whereas well-designed RCTs, such as that of Miles et al. [33], make a point to address the large population of facial fracture patients who are “lost to follow-up,” the quality of post-operative follow-up is not well documented in most of the available literature. It is possible that this inadequacy skews the SSI incidence toward either over- or under-reporting, as patients who develop an SSI may be more likely to follow up or may choose to follow up at another institution.

Finally, there are many patient-specific parameters that we were unable to address because of inconsistent reporting across the literature. Factors such as tobacco use, diabetes mellitus, poor oral hygiene (especially dentition), substance abuse, and age have been linked to a higher risk of SSI after facial fractures [56,57]. Whereas these factors could confound the association between SSI and PAP, three prospective studies included in this analysis did control for patient factors and came to the same conclusion—PAP does not prevent SSI [12–14].

In conclusion, this systematic review found that antibiotic prophylaxis beyond 24 hours post-operatively was not associated with a lower incidence of SSIs, regardless of the location of the facial fracture. Extended antibiotic prophylaxis of patients with mandibular fractures undergoing ORIF




FIG. 7. Summary of generalized estimating equation (GEE) estimates of odds ratios of developing post-operative surgical site infection according to antibiotic treatment group in patients with mandibular fractures undergoing open reduction and internal fixation. Note that all confidence intervals contain the value 1.




FIG. 8. Forest plot of Mantel-Hanszel (MH) estimates of odds ratios (OR) of post-operative surgical site infection among patients in extended antibiotic group (antibiotics continued >72 h post-operatively) relative to peri-operative antibiotic group (antibiotics discontinued <24 h from surgery) in patients with mid-face fractures.

actually was associated with a higher risk of SSI. We suggest that post-operative antibiotics in patients with facial fractures should be limited to 24 hours or less. Unfortunately, the data are too heterogenous to offer a definitive statement on antibiotic selection. The development and implementation of practice guidelines regarding antibiotic stewardship in surgical facial fracture management is needed.

Author Disclosure Statement

None of the authors of this manuscript has significant financial disclosures to make related to this project.

References

1. Allareddy V, Allareddy V, Nalliah RP. Epidemiology of facial fracture injuries. *J Oral Maxillofac Surg* 2011;69:2613–2618.

2. Sethi R KV, Kozin ED, Lee DJ, et al. Epidemiological survey of head and neck injuries and trauma in the United States. *Otolaryngology* 2014;151:776–784.

3. Hwang K, You SH. Analysis of facial bone fractures: An 11-year study of 2,094 patients. *Indian J Plast Surg* 2010; 43:42–48.

4. Zallen RD, Curry JT. A study of antibiotic usage in compound mandibular fractures. *J Oral Surg* 1975;33:431–434.

5. Chole RA, Yee J. Antibiotic prophylaxis for facial fractures: A prospective, randomized clinical trial. *Arch Otolaryngol Head Neck Surg* 1987;113:1055–1057.

6. Andreasen JO, Jensen SS, Schwartz O, et al. A systematic review of prophylactic antibiotics in the surgical treatment of maxillofacial fractures. *J Oral Maxillofac Surg* 2006;64: 1664–1668.

7. Malekpour M, Bridgham K, Neuhaus N, et al. Utility of prophylactic antibiotics in nonoperative facial fractures. *J Craniofac Surg* 2016;27:1677–1680.

8. Mottini M, Wolf R, Soong PL, et al. The role of postoperative antibiotics in facial fractures: Comparing the efficacy of a 1-day versus a prolonged regimen. *J Trauma Acute Care Surg* 2014;76:720–724.

9. Zosa BM, Elliott CW, Kurlander DE, et al. Facing the facts on prophylactic antibiotics for facial fractures: 1 day or less. *J Trauma Acute Care Surg* 2018;85:444–450.

10. Baliga SD, Bose A, Jain S. The evaluation of efficacy of post-operative antibiotics in the open reduction of the zygomatic and mandibular fracture: A prospective trial. *J Maxillofac Oral Surg* 2014;13:165–175.

11. Lovato C, Wagner JD. Infection rates following perioperative prophylactic antibiotics versus postoperative extended regimen prophylactic antibiotics in surgical management of mandibular fractures. *J Oral Maxillofac Surg* 2009;67:827–832.

12. Schaller B, Soong PL, Zix J, et al. The role of postoperative prophylactic antibiotics in the treatment of facial fractures: A randomized, double-blind, placebo-controlled pilot clinical study 2: Mandibular fractures in 59 patients. *Br J Oral Maxillofac Surg* 2013;51:803–807.

13. Soong PL, Schaller B, Zix J, et al. The role of postoperative prophylactic antibiotics in the treatment of facial fractures: A randomised, double-blind, placebo-controlled pilot clinical study 3: Le Fort and zygomatic fractures in 94 patients. *Br J Oral Maxillofac Surg* 2014;52:329–333.

14. Zix J, Schaller B, Iizuka T, et al. The role of postoperative prophylactic antibiotics in the treatment of facial fractures: A randomised, double-blind, placebo-controlled pilot clinical study 1: Orbital fractures in 62 patients. *Br J Oral Maxillofac Surg* 2013;51:332–336.

15. Shridharani SM, Berli J, Manson PN, et al. The role of postoperative antibiotics in mandible fractures: A systematic review of the literature. *Ann Plastic Surg* 2015;75: 353–357.

16. Bidell MR, Palchak M, Mohr J, et al. Fluoroquinolone and third-generation-cephalosporin resistance among hospitalized patients with urinary tract infections due to *Escherichia coli*: Do rates vary by hospital characteristics and geographic region? *Antimicrob Agents Chemother* 2016;60:3170–3173.

17. Pallett A, Hand K. Complicated urinary tract infections: Practical solutions for the treatment of multiresistant gram-negative bacteria. *J Antimicrob Chemother* 2010;65 (Suppl 3):iii25–iii33.

18. Zilberberg MD, Nathanson BH, Marcella S, et al. Hospital readmission with *Clostridium difficile* infection as a secondary diagnosis is associated with worsened outcomes and greater revenue loss relative to principal diagnosis: A retrospective cohort study. *Medicine* 2018;97:e12212.

19. Pirson M, Poirrier JE, Joubert S, et al. Evaluation of the cost and length of hospital stays related to the management of an intestinal *Clostridium difficile* infection. *Acta Gastroenterol Belg* 2018;81:263–268.

20. Habib AM, Wong AD, Schreiner GC, et al. Postoperative prophylactic antibiotics for facial fractures: A systematic review and meta-analysis. *Laryngoscope* 2019;29:82–96.

21. Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. *N Engl J Med* 2015;372:1996–2005.

22. Schein M, Assalia A, Bachus H. Minimal antibiotic therapy after emergency abdominal surgery: A prospective study. *Br J Surg* 1994;81:989–991.

23. Rodriguez L, Jung HS, Goulet JA, et al. Evidence-based protocol for prophylactic antibiotics in open fractures: Improved antibiotic stewardship with no increase in infection rates. *J Trauma Acute Care Surg* 2014;77:400–407.

24. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *Int J Surg* 2010;8:336–341.
25. National Health and Medical Research Council. NHMRC Levels of Evidence and Grades for Recommendations for Guideline Developers. Canberra, Australia. National Health and Medical Research Council; 2009.
26. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *J Epidemiol Commun Health* 1998;52:377–384.
27. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst* 1959;22:719–748.
28. Abubaker AO, Rollert MK. Postoperative antibiotic prophylaxis in mandibular fractures: A preliminary randomized, double-blind, and placebo-controlled clinical study. *J Oral Maxillofac Surg* 2001;59:1415–1419.
29. Bouchard C, Perreault MH. Postoperative complications associated with the retromandibular approach: A retrospective analysis of 118 subcondylar fractures. *J Oral Maxillofac Surg* 2014;72:370–375.
30. Domingo F, Dale E, Gao C, et al. A single-center retrospective review of postoperative infectious complications in the surgical management of mandibular fractures: Postoperative antibiotics add no benefit. *J Trauma Acute Care Surg* 2016;81:1109–1114.
31. Gaal A, Bailey B, Patel Y, et al. Limiting antibiotics when managing mandible fractures may not increase infection risk. *J Oral Maxillofac Surg* 2016;74:2008–2018.
32. Kneipil GJ, Loukota RA. Outcomes of prophylactic antibiotics following surgery for zygomatic bone fractures. *J Cranio-Maxillo-Fac Surg* 2010;38:131–133.
33. Miles BA, Potter JK, Ellis E 3rd. The efficacy of postoperative antibiotic regimens in the open treatment of mandibular fractures: A prospective randomized trial. *J Oral Maxillofac Surg* 2006;64:576–582.
34. Singh RP, Carter LM, Whitfield PH. Antimicrobial prophylaxis in open reduction and internal fixation of compound mandibular fractures: A collaborative regional audit of outcome. *Br J Oral Maxillofac Surg* 2013;51:444–447.
35. Theriot BA, Van Sickels JE, Triplett RG, et al. Intraosseous wire fixation versus rigid osseous fixation of mandibular fractures: A preliminary report. *J Oral Maxillofac Surg* 1987;45:577–582.
36. Adalarasan S, Mohan A, Pasupathy S. Prophylactic antibiotics in maxillofacial fractures: A requisite? *J Craniofac Surg* 2010;21:1009–1011.
37. Boffano P, Rocchia F. Bilateral mandibular angle fractures: Clinical considerations. *J Craniofac Surg* 2010;21:328–331.
38. Bui P, Demian N, Beetar P. Infection rate in mandibular angle fractures treated with a 2.0-mm 8-hole curved strut plate. *J Oral Maxillofac Surg* 2009;67:804–808.
39. Campos GB, Lucena EE, da Silva JS, et al. Efficacy assessment of two antibiotic prophylaxis regimens in oral and maxillofacial trauma surgery: Preliminary results. *Int J Clin Exp Med* 2015;8:2846–2852.
40. Heit JM, Stevens MR, Jeffords K. Comparison of ceftriaxone with penicillin for antibiotic prophylaxis for compound mandible fractures. *Oral Surg Oral Med Oral Pathol Oral Radiol Endodont* 1997;83:423–426.
41. Lauder A, Jalisi S, Spiegel J, et al. Antibiotic prophylaxis in the management of complex midface and frontal sinus trauma. *Laryngoscope* 2010;120:1940–1945.
42. Lindqvist C, Kontio R, Pihakari A, et al. Rigid internal fixation of mandibular fractures: An analysis of 45 patients treated according to the ASIF method. *Int J Oral Maxillofac Surg* 1986;15:657–564.
43. Maloney PL, Lincoln RE, Coyne CP. A protocol for the management of compound mandibular fractures based on the time from injury to treatment. *J Oral Maxillofac Surg* 2001;59:879–884.
44. Pham-Dang N, Barthelemy I, Orliaguet T, et al. Etiology, distribution, treatment modalities and complications of maxillofacial fractures. *Med Oral Patol Oral Cirug Bucal* 2014;19:e261–e269.
45. Huang W, Lynham A, Wullschlegler M. Orbitozygomatic fracture repairs: Are antibiotics necessary? *Cranio-maxillofac Trauma Reconstruct* 2015;8:271–276.
46. Gray LN, Kalimuthu R, Jayaram B, et al. A retrospective study of treatment of orbital floor fractures with the maxillary sinus approach. *Br J Plast Surg* 1985;38:113–115.
47. Villarreal PM, Monje F, Morillo AJ, et al. Porous polyethylene implants in orbital floor reconstruction. *Plast Reconstr Surg* 2002;109:877–885.
48. Wladis EJ. Are post-operative oral antibiotics required after orbital floor fracture repair? *Orbit* 2013;32:30–32.
49. Brooke SM, Goyal N, Michelotti BF, et al. A multidisciplinary evaluation of prescribing practices for prophylactic antibiotics in operative and nonoperative facial fractures. *J Craniofac Surg* 2015;26:2299–2303.
50. Mundinger GS, Borsuk DE, Okhah Z, et al. Antibiotics and facial fractures: Evidence-based recommendations compared with experience-based practice. *Cranio-maxillofac Trauma Reconstruct* 2015;8:64–78.
51. Balch A, Wendelboe AM, Vesely SK, et al. Antibiotic prophylaxis for surgical site infections as a risk factor for infection with *Clostridium difficile*. *PLoS One* 2017;12:e0179117.
52. Harbarth S, Cosgrove S, Carmeli Y. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. *Antimicrob Agents Chemother* 2002;46:1619–1628.
53. Kuhlen JL Jr, Camargo CA Jr, Balekian DS, et al. Antibiotics are the most commonly identified cause of perioperative hypersensitivity reactions. *J Allergy Clin Immunol Pract* 2016;4:697–704.
54. Malanchuk VO, Kopchak AV. Risk factors for development of infection in patients with mandibular fractures located in the tooth-bearing area. *J Cranio-Maxillo-Fac Surg* 2007;35:57–62.
55. Aaland MO, Marose K, Zhu TH. The lost to trauma patient follow-up: A system or patient problem. *J Trauma Acute Care Surg* 2012;73:1507–1511.
56. Furr AM, Schweinfurth JM, May WL. Factors associated with long-term complications after repair of mandibular fractures. *Laryngoscope* 2006;116:427–430.
57. Senel FC, Jessen GS, Melo MD, et al. Infection following treatment of mandible fractures: The role of immunosuppression and polysubstance abuse. *Oral Surg Oral Med Oral Pathol Oral Radiol Endodont* 2007;103:38–42.

Address correspondence to:
 Dr. Patrick T. Delaplain
 Department of Surgery
 University of California
 Irvine Medical Center
 333 City Boulevard West
 Suite 1600
 Orange, CA 92868

E-mail: pdelapla@uci.edu

This article has been cited by:

1. Miles J. Pfaff, Leila Musavi, Maxwell M. Wang, Christos S. Haveles, Claire Liu, Kameron S. Rezzadeh, Justine C. Lee. 2021. Oral Flora and Perioperative Antimicrobial Interventions in Cleft Palate Surgery: A Review of the Literature. *The Cleft Palate-Craniofacial Journal* **58**:8, 990-998. [[Crossref](#)]
2. Ashton Christian, Beatrice J. Sun, Nima Khoshab, Areg Grigorian, Christina Y. Cantwell, Sean A. Melucci, Allison C. Hu, Catherine M. Kuza, Michael E. Lekawa, Jeffry Nahmias. 2021. Facial Fractures Have Similar Outcomes When Managed by Either Otolaryngology or Plastic Surgery: Encounters From a Single Level I Trauma Center. *Craniomaxillofacial Trauma & Reconstruction* 194338752110206. [[Crossref](#)]
3. Aaron M. Kearney, Nikhil Shah, James Zins, Arun K. Gosain. 2021. Fifteen-Year Review of the American Board of Plastic Surgery Maintenance of Certification Tracer Data: Clinical Practice Patterns and Evidence-Based Medicine in Zygomatico-Orbital Fractures. *Plastic & Reconstructive Surgery* **147**:6, 967e-975e. [[Crossref](#)]
4. Brenda M. Zosa, Husayn A. Ladhani, Nitin Sajankila, Charles W. Elliott, Jeffrey A. Claridge. 2021. Pre-Operative Antibiotic Agents for Facial Fractures: Is More than One Day Necessary?. *Surgical Infections* **22**:5, 516-522. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
5. Joseph D. Forrester, Chris J. Wolff, Jeff Choi, Kristin P. Colling, Jared M. Huston. 2021. Surgical Infection Society Guidelines for Antibiotic Use in Patients with Traumatic Facial Fractures. *Surgical Infections* **22**:3, 274-282. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]